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Several basic and clinical studies have indicated that the aggres-
siveness of solid tumours such as the growth, invasion, and
metastatic potential is dependent on angiogenesis (Gimbrone et al,
1972; Liotta et al, 1974; Folkman 1990; Folkman et al, 1989).
Vascularization supplies nutrition and oxygen to proliferating
tumour cells (Gimbrone et al, 1974). Several reports have demon-
strated a positive correlation between an increased number of new
vessels and the development of metastasis (Gimbrone et al, 1974;
Liotta et al, 1974; Liotta et al, 1991). It has been reported that
neovasularity assessed by intratumoral microvessel density
(MVD) correlates with clinicopathologic factors and the prognosis
of a variety of cancers (Yamazaki et al, 1994; Maeda et al, 1995;
Brawer, 1996; Gasparini et al, 1996; Takabayashi et al, 1996). 
To date, many angiogenic factors have been identified as
follows: basic fibroblast growth factor, vascular endothelial
growth factor (VEGF), platelet-derived endothelial cell growth
factor, hepatocyte growth factor, transforming growth factor,
epidermal growth factor, tumour necrosis factor-a, interleukin-8
and so on. It is now thought that expression of the tumour cell
derived angiogenic factors is specific to each tumour and depen-
dent on the process of tumour growth and spreading. Several
studies have noted that the level of expression of VEGF, which is a
strong angiogenic factor, correlates with neovascularity and with
tumour progression in human colon cancer (Takahashi et al, 1995),
human brain tumour (Takano et al, 1996), human breast cancer
(Maeda et al, 1996), and several experimental tumour models
(Miller et al, 1994; Zhang et al, 1995; Claffey et al, 1996). VEGF
secreted from tumours may contribute to tumour growth, invasion
and metastasis not only via an autocrine pathway to tumour cells,
but via a paracrine pathway to surrounding microvessels
(Takahashi et al, 1995). Overall, determination of the degree of
neoangiogenesis is emerging as one of the powerful prognostic
tools. 
Recent studies on a large number of soft tissue sarcoma cases
have claimed that the grade of the tumour, size of the tumour and
tumour depth are independent prognostic factors (Gaynor et al,
1992; Coindre et al, 1996). There is a general consensus that the
size of tumour tissue is an important and easily obtainable para-
meter of tumour growth and that the growth of tumour is largely
dependent on neovascularity in solid tumours. However, it remains
unclear whether the level of angiogenic activity correlates with the
prognosis of soft tissue sarcomas. Soft tissue sarcomas represent a
heterogeneous group of relatively rare malignant tumours with
many histologic types. Because angiogenesis is essential for
tumour growth, the development of local recurrence and metas-
tasis, tumour angiogenesis assessed by MVD and the level of
VEGF expression may be good prognostic factors for soft tissue
sarcomas, regardless of histologic type. 
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Summary Previous studies have shown that the prognosis of patients who have tumours with high microvessel density (MVD) is worse than that
of patients who have a lower density in a variety of cancers. In this study, we investigated the clinical relevance of neovascularity assessed by MVD
and the concentration of vascular endothelial growth factor (VEGF) in the tumour tissue of patients with soft tissue sarcoma in comparison with
major clinicohistologic parameters by univariate and multivariate analysis. In 115 patients with soft tissue sarcoma, MVD was measured by
counting vessels stained with factor VIII antibody. The concentration of VEGF in the tumour tissue was determined by enzyme-linked
immunosorbent assay. These parameters were then compared with disease outcome. The concentration of VEGF in the tumour tissue, but not
MVD, was found to be correlated with disease outcome in patients with soft tissue, sarcoma. VEGF concentration in the tumour tissue showed a
relationship with the clinical stage and histologic grade of the tumour. There was no significant difference in the levels of tissue VEGF concentration
and MVD among soft tissue sarcomas classified according to histologic type. The level of tissue VEGF concentration in patients who had
subsequent local recurrence and metastasis were significantly higher than the respective values in patients who did not have such disease
outcome. No significant correlation existed between MVD and the concentration of VEGF in the tumour tissue. Univariate analysis showed that a
high tissue VEGF concentration was associated with poor overall survival of the patient and a greater probability that local recurrence and
metastasis had occurred. Multivariate analysis revealed that the tissue concentration of VEGF is an independent prognostic factor for the disease
outcome of patients with soft tissue sarcoma. VEGF concentration in the tumour tissue, but not MVD, is an additional prognostic parameter for
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In the present study, to evaluate whether angiogenic activity has
any impact on the prognosis of patients with soft tissue sarcoma,
we investigated whether a relationship exists between MVD, the
concentration of VEGF by enzyme-linked immunosorbent assay
(ELISA) in the tumour tissue, and disease outcome. 
MATERIALS AND METHODS 
Patients and tumour specimens 
The subjects consisted of patients who underwent follow-up care
at Toyama Medical and Pharmaceutical University Hospital and
cooperative Cancer Center Hospital for verified cases of soft tissue
sarcoma between 1990 and 1996. All patients who met the
following criteria were included in this study: (1) the patient had a
newly diagnosed primary tumour; (2) the tumour was histologi-
cally classified as a soft tissue sarcoma; (3) the tumour was radi-
cally resectable; (4) the patient had no other disease that would
influence angiogenesis, such as wound healing, rheumatoid
arthritis, and diabetic retinopathy. 115 patients met the study
criteria. These included 58 men and 57 women; the average age
was 61.5 ± 20.4 y at diagnosis (mean ± standard deviation (SD);
range, 28 to 77 y). The observation period ranged between 63 and
176 months (mean ± SD, 91 ± 11 months). Surgery with curative
intent was performed in all of the patients. Simple local excision
was performed in 12 patients (7.0%); wide resection in 95 patients
(82.6%); and amputation in 8 patients (10.4%). Surgical treatment
was preceded by radiotherapy in 13 patients; chemotherapy in 55
patients; and both radiotherapy and chemotherapy in 10 patients.
After the surgery, 3 patients received radiotherapy, 7 patients
received chemotherapy, and 5 patients received both radiotherapy
and chemotherapy. All of the tumours were histologically
confirmed. The histologic grade and clinical stage of soft tissue
sarcoma were documented based on the criteria of the UICC TNM
Classification of malignant tumours (Hermanek and Sobin 1992).
Each tumour was graded as having a high, moderate and low
malignancy grade using the National Cancer Institute grading
system (Mandard et al, 1989). The characteristics of tumour
patients are summarized in Table 1. All patients gave informed
consent for participation in this study. 
The resected tumour specimens were immediately fixed in 10%
phosphate-buffered formalin for 48 hours and embedded in
paraffin. Sections of 6 mm in thickness were made and mounted on
glass slides. Other parts of tissues were immediately frozen with
liquid nitrogen and stored at –80˚C. The tumour tissues were
homogenated with a motor-driven Teflon pestle for 5 minutes on
ice in 1 ml of extraction buffer (25 mM Tris (pH 7.4), 100 mM
NaCl, 20 mM NH4HCO3) per 100 mg tissue wet weight, and the
tissue extract obtained after centrifugation at 15 000 rpm for 20
minutes at 4˚C was aliquoted to a 200-mM vial, stored at –80˚C,
and used for ELISA. 
Immunohistochemical staining 
Tissue sections were deparaffinized and incubated with 10%
normal goat serum in phosphate-buffered saline (PBS) for 30
minutes. The sections were incubated with 200 mg ml–1 of anti-
factor VIII mAb (1:50) (Dako, Santa Barbara, CA) for 60 minutes
at room temperature. Purified mouse IgG (Cappel, West Chester,
PA) at the same protein concentration as that in the tissue section
was used as a negative control. The sections were incubated with
biotin-conjugated goat anti-mouse (1:100, Santa Cruz Biotechno-
logy, Santa Cruz, CA) for 10 minutes, followed by washing in PBS
for 5 minutes, followed by washing in PBS for 5 minutes, and then
stained with freshly prepared aminoethylcarbazole solution for 10
minutes, followed by a 5-minutes wash in tap water. The sections
were counterstained with haematoxylin and mounted with aqueous
mounting media. 
Microvessel counting 
Each slide was studied for antigen expression by 2 investigators.
Any single brown-stained cell which indicates an endothelial cell
that stained for the presence of factor VIII or a cluster of cells
clearly distinguishable from the background was counted as a
vessel. Branching structures were counted as a single vessel,
unless there was a break in the continuity of the structure. The
stained sections were screened at 5 times magnification, to identify
the areas of highest vascular density. Sclerotic areas where
microvessels were sparse and areas immediately adjacent to
benign tissue were not considered in the vessel count. After the
area of highest neovascularization was identified, individual
vessel counts were performed at ´ 200 magnification (0.739 mm2
per field). 
Table 1 Characteristics of tumour patients 
Counts 
Histological type Number of patients Grade of malignancy  Size Stage 
Low + Moderate / High < 5 cm / ³ 5 cm I + II / III + IV 
Chondrosarcoma 18 8/10 10/8 9/9 
MFH 15 6/9 7/8 8/7 
Ewing’s sarcoma 15 0/15 6/9 6/9 
Leiomyosarcoma 12 6/6 6/6 7/5 
Synovial sarcoma 12 0/12 5/7 6/6 
Liposarcoma 11 6/5 7/4 5/6 
Fibrosarcoma 10 5/5 5/5 4/6 
Unclassified sarcoma 10 6/4 7/3 5/5 
Rhabdomyosarcoma 9 5/4 5/4 4/5 
Malignant schwannoma 3 1/2 3/0 1/2 
MFH = malignant fibrosis histiocytoma. 1612 K Yudoh et al 
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Measurement of VEGF in tumour tissue sample 
The concentration of VEGF in the tumour extract was measured
by ELISA as described previously (Takano et al, 1996). Each well
of a 96-well microtitre plate was sensitized with 100 ml of 10 mg
ml–1 of anti-human VEGF monoclonal antibody (mAb) (Dako) at
room temperature for 1 hour. The plate was washed with PBS
containing 0.05% Tween 20 and 0.1% bovine serum albumine
(PBS-T-BSA). 100 ml per well of standard VEGF (0.1–1000 pg
ml–1: Dako) diluted in PBS-T-BSA or tissue sample diluted with an
equal volume of PBS-T-BSA was added to the wells and incubated
for 2 hours at 22˚C. After washing the wells 6 times, anti-human
VEGF mAb (Sigma) used at a 1:1000 dilution in PBS-T-BSA was
reacted in each well at 22˚C for 2 hours. The wells were washed 6
times, and then peroxidase-conjugated anti-IgG antibody (Dako)
was added to each well and allowed to react for 2 hours at 37˚C.
After a final wash, plates were incubated with 3.75 mmol l–1
O-phenylenediamine, 1 mmol l–1 H2O2 in 24 mmol l–1 sodium
citrate, 51 mmol l–1 Na2HPO4, pH 5.0 for 15 minutes. The reaction
was stopped by adding 100 mL 2 mol l–1 H2SO4 and absorbance
was read at 492 nm with a background subtraction at 620 nm. All
standards and samples were measured in duplicate. 
Statistical analysis 
Results were expressed as mean ± standard deviation (SD). The
variances were analysed by the F test. Student’s t-test (equal vari-
ance groups) and the Wilcoxon U test (unequal variance group)
were used for statistical comparisons between 2 groups.
Correlation coefficient was determined by Spearman’s rank corre-
lation test. A P value of less than 0.05 was considered to be statis-
tically significant. Date of diagnosis was considered as the time of
origin. For survival curves, we considered as an event, all deaths,
whatever their cause. For the local recurrence-free interval, we
considered strictly local recurrence as an event. For patients who
died without any local recurrence, they were considered censored
data at the time of death. For metastasis-free interval, we consid-
ered the first metastasis as an event. For patients who died without
any metastasis, they were considered censored data at the time of
death. The overall observed survival functions and probabilities
were estimated using the Kaplan–Meier method. The log rank test
was used to detect differences between survival curves for strati-
fied variables. Univariate and multivariate analyses were
performed using Cox’s proportional hazard model. For multi-
variate analysis, VEGF concentration in the tumour tissue were
separately adjusted to the clinocopathologic parameters through
which the independent prognostic value of these parameters was
determined. 
RESULTS 
MVD and VEGF concentration in tumour tissue
Photomicrograph of representative soft tissue sarcoma stained for
factor VIII is shown in Figure 1. No significant association was
observed between MVD and histologic type of soft tissue
sarcomas (data not shown). In patients with soft tissue sarcoma,
there was no statistical correlation between MVD and the VEGF
concentration in the tumour tissue (P = 0.075, r = 0.433). 
Levels of MVD and VEGF concentration in the tumour
tissue in relation to clinical stage and histologic grade 
A correlation between MVD and stage of the disease did not
existed (Table 2). In contrast, the concentration of VEGF in the
tumour tissue correlated with the clinical stage of the disease. 
There was a significant correlation between the grade of
histologic malignancy of the tumour and tissue VEGF concentra-
tion, but not with MVD. At higher grades, tissue VEGF
concentration increased (Table 2). 
Correlation between MVD and VEGF concentration in
the tumour tissue and clinical variables 
The mean MVD in patients who developed local recurrence or
metastasis in the patients who developed metastasis showed no
significant difference compared with the mean MVD in those who
AB
Figure 1 Representative immunohistochemical staining for factor VIII in soft
tissue sarcoma. (A) Haematoxylin and eosin staining (x 200). (B) Blood
vessels were identified by staining endothelial cells for factor VIII (x 200) 
Table 2 Levels of MVD and VEGF concentration in relation to clinical stage and
histologic grade in patients with soft tissue sarcoma 
Variable Number MVD (/mm2) VEGF concentration in the
of patients (mean ± SD) tumour tissue (mMol mg–1
protein) (mean ± SD) 
Stage 
I + II 55 29.5 ± 10.4 1.7 ± 0.8  ]*
III 32 33.1 ± 15.8 3.3 ± 1.4 
IV 28 35.4 ± 12.6 6.4 ± 2.4  ]* ]**
Grade 
Low + Moderate 43 32.5 ± 14.7  2.8 ± 1.4 
High 72 36.8 ± 14.8 4.9 ± 2.1 ]*
MVD = microvessel density; VEGF = vascular endothelial growth factor. 
*P < 0.05, **P < 0.01, SD = standard deviation. Tissue VEGF concentration in soft tissue sarcomas 1613
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did not (P = 0.087 and P = 0.075, respectively) (Table 3). The
mean tumour VEGF concentration in patients who developed
either local recurrence or metastasis was higher than in those who
did not develop the respective condition (P < 0.001 and P = 0.004,
respectively) (Table 3). 
MVD, level of VEGF expression, and prognosis 
In the present study, the MVD of patients with soft tissue sarcoma
was 35.4 ± 11.2 /mm2, and the tissue VEGF concentration was
2.48 ± 0.98 mMol mg–1 protein. We divided the patients into those
with high MVD (> 35/mm2), and those with low MVD (≤ 35/
mm2), based on the median value. We also divided the patients into
those with high tissue VEGF concentration (> 2.5 mMol mg–1
protein), and those with low tissue VEGF concentration (≤ 2.5
mMol mg–1 protein), also based on the median value. The prog-
nosis of those in the high tissue VEGF concentration group was
significantly worse than those in the low tissue VEGF concentra-
tion group (Figure 2). However, there was no significant differ-
ence in the prognosis between the high MVD group and the low
MVD group. 
Univariate and multivariate analyses 
Table 4 shows the results of the univariate analysis for prognostic
parameters for overall survival, the local recurrence-free and
metastasis-free survival. In univariate analysis, tumour size, clin-
ical stage, grade of histologic malignancy, tissue VEGF concentra-
tion had a significant impact on overall mortality and metastasis 
(P < 0.01). Clinical stage, grade of histologic malignancy, and
tissue VEGF concentration significantly affected local recurrence-
free survival (P < 0.01), and there was a trend (P = 0.05) for 2 vari-
ables: tumour size and localization (Table 4). Univariate analysis
resulted in identification of VEGF concentration in the tumour
tissue, which had an association with the overall survival, the local
recurrence and metastasis of the patients. 
The effects of variables presumably associated with prognosis
were studied by multivariate analysis. Tissue VEGF concentration
was significantly correlated with a poorer overall survival, the
local recurrence-free and metastasis-free survival (Table 5). The
parameter emerged as an independent prognostic parameter. 
DISCUSSION 
We hypothesized that neovascularity as well as angiogenic factor
involved in its regulation play a role in determining the prognosis
of soft tissue sarcomas. We found that the concentration of VEGF,
but not microvessel count, in the tumour tissue was significantly
correlated with the prognosis, stage of disease, and histologic
grade of soft tissue sarcomas. In addition, tumours associated with
local recurrence or metastasis showed a significantly higher tissue
VEGF concentration than those without either. 
Recent independent studies of a large series of soft tissue
sarcomas showed that histologic tumour grade, tumour depth and
tumour size were independent prognostic factors (Gaynor et al,
1992; Coindre et al, 1996). In the current study, Cox proportional
hazard multivariate analysis revealed that histologic grade was the
most valuable independent prognostic factor in patients with soft
tissue sarcoma. Moreover, tissue VEGF concentration measured
by ELISA was also an independent prognostic factor for patients
with soft tissue sarcomas. Similar results have been reported in
studies on several cancers including human colon cancer
(Takahashi et al, 1995), brain tumour (Takano et al, 1996), and
gastric cancer (Maeda et al, 1996). 
However, in the present study, the count of microvessels stained
with factor VIII antibody was not correlated with the prognosis of
soft tissue sarcomas. Generally speaking, neovascularity assessed
by the microvessel counting in the tumour tissue has a prognostic
value in a variety of cancers (Yamazaki et al, 1994; Maeda et al,
1995; Brawer, 1996; Gasparini et al, 1996; Takabayashi et al,
1996). In addition, the density of microvessels was not correlated
with the tissue VEGF concentration measured by ELISA in soft
tissue sarcomas. Microvessel counting in the tumour tissue may
not accurately represent the angiogenic capacity in soft tissue
sarcomas. Other techniques may be necessary to predict the neoan-
giogenesis of soft tissue sarcomas. 
Table 3 Levels of MVD and VEGF concentration in relation to clinical variables in patients with soft
tissue sarcoma 
Variable Number of  MVD (/mm2)  VEGF concentration in the
patients (mean ± SD) tumour tissue (mMol mg–1 protein)
(mean ± SD) 
Local recurrence (–) 64 32.4 ± 11.8  1.9 ± 0.7 ]** Local recurrence (+) 51 35.6 ± 12.4  6.3 ± 1.9 
Metastasis (–) 63 29.2 ± 16.3 2.3 ± 1.7 ]** Metastasis (+) 52 31.4 ± 14.5 4.9 ± 1.6 
MVD = microvessel density; VEGF = vascular endothelial growth factor. 
**P < 0.01; SD = standard deviation. 
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Figure 2 (A) Overall survival curves according to high and low microvessel
density (MVD) in the tumour tissue of patients with soft tissue sarcoma.
(B) Overall survival curves according to high and low concentration of
vascular endothelial growth factor (VEGF) in the tumour tissue of patients
with soft tissue sarcoma 1614 K Yudoh et al 
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In our other study, the level of bFGF expression was not corre-
lated with the microvessel density in soft tissue sarcomas,
although bFGF expression was observed in the tumour tissue (data
not shown). Our data was consistent with the findings of Takahashi
et al, who demonstrated that no significant correlation was
observed between the expression of bFGF and the microvessel
density in colon cancer. Similar results have also been reported in
gastric cancer (Takahashi et al, 1996). The reason why the level of
VEGF or bFGF expression did not correlate with the density of
microvessels in soft tissue sarcomas still remains unclear. Further
studies are needed to clarify this discrepancy in soft tissue
sarcomas. Angiogenic factors secreted from tumours may
contribute to all processes of tumour advancement not only via a
paracrine pathway to surrounding microvessels, but also via an
autocrine pathway to tumour cells (Berkman et al, 1993; Boocock
et al, 1995). To confirm the hypothesis that VEGF or bFGF plays a
role in the tumour aggressiveness and the neoangiogenesis in soft
tissue sarcomas, it must be demonstrated that receptors for each
factor are present on tumour cells and tumour endothelia. We are
currently studying the significance of the level of expression of
VEGF and bFGF and their receptors in soft tissue sarcomas. 
In the present study, in the sera from soft tissue sarcoma
patients, VEGF levels were within normal range, even in the case
with extremely high levels of VEGF in the tumour tissue (data not
shown). Failure to detect VEGF in the sera from soft tissue
sarcoma, as well as several types of cancer, might be explained by
rapid binding of VEGF to cell receptors or to extracellular matrix,
resulting in the clearance of VEGF from the circulation (Yeo et al,
1993). 
It is difficult to choose a histological site to study microvessel
count and VEGF expression in soft tissue sarcomas, because a
solid tumour such as a soft tissue sarcoma does not occur in a
single layer of the bowel except in its earliest stages. Several
studies have demonstrated that microvessel density at the invasive
Table 5 Multivariate analysis for overall survival, local recurrence and metastasis 
Cox’s hazard ratio (95% CI) and P value 
Parameters Overall survival Local recurrence  Metastasis 
Tissue VEGF concentration 1.94 (1.03–3.60) 0.025  1.32 (1.34–3.90) 0.001 1.13 (1.09–1.18) < 0.001 
Tumour size 1.08 (1.03–1.12) 0.255 1.01 (0.99–1.13) 0.395 1.02 (0.98–1.08) 0.355 
Clinical stage 6.92 (2.37–20.12) 0.007 2.56 (0.95–6.95) 0.067 1.72 (0.72–4.04) 0.224 
Grade of histologic malignancy 2.44 (0.95–6.85) 0.019 2.10 (0.43–8.85) 0.378 1.87 (0.61–5.74) 0.254 
VEGF = vascular endothelial growth factor; CI = confidence interval. 
Table 4 Univariate analysis of clinicopathologic parameters and MVD and tissue VEGF concentration in relations to overall survival, local recurrence-and
metastasis-free survival in patients with soft tissue sarcoma 
Parameters Number of  Overall 5-year  P value Recurrence-free 5-year  P value Metastasis-free 5-year  P value 
patients survival rate (%) survival rate (%) survival rate (%)
Age (year) 
< 50 55 69.8 0.4 62.5  0.6 68.4 0.5 
³ 50 60 63.5 65.5 65.6
Sex 
Male 58 65.2 0.9 64.6 0.7 63.5 0.9 
Female 57 64.8 61.6 65.9 
Tumour size 
< 5 cm 61 83.4 < 0.001  75.4 0.05 77.4 < 0.001 
³ 5 cm 54 54.5 65.3 53.5
Localization 
extremity 68 61.5 0.08 69.4 0.05 65.4 0.6 
trunk 47 58.1 58.9 64.6
Stage 
I + II 55 85.3 < 0.001  78.3 0.003 75.2 0.002 
III + IV 60 50.6 49.2  42.8 
Grade 
Low + Moderate 43 76.5 0.001  86.2 < 0.001 71.3 < 0.001 
High 72 48.5 58.6 40.2
MVD (mm2) 
< 35 58 64.5 0.4 67.3  0.2 57.3 0.4 
³ 35 57 60.2 62.5 50.9
VEGF (mMol mg–1
protein) 
< 2.5 63 66.6 < 0.001  71.5 < 0.001 66.5 0.003 
³ 2.5 52 40.2 47.5 46.5
MVD = microvessel density; VEGF = vascular endothelial growth factor. Tissue VEGF concentration in soft tissue sarcomas 1615
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edge is significantly higher than that within the tumour, and that
the highest level of angiogenic activity occurs at the invasive edge
of the tumour (Takahashi et al, 1995; Takano et al, 1996). We also
found in another in vivo study that hot spots of microvessels were
observed at the invasive edge of the tumour tissue in tumour-
bearing mice; a significant correlation existed between the level of
expression of VEGF at the invasive edge, and tumour growth and
metastasis (data not shown). These findings suggest that the inva-
sive edge of the tumour is the most active area in local invasion, as
well as metastasis. In the current study, we chose the highest
density of microvessels in the tumour tissue. 
The current study provides evidence to support the hypothesis
that the concentration of VEGF in the tumour tissue is strongly
linked with disease outcome and with the prognosis of patients
with soft tissue sarcomas. If VEGF expression in the tumour tissue
proves to be reliable prognostic factors, patients at high risk for
developing local recurrence or metastasis, can be selected for adju-
vant therapy. It has been reported that anti-VEGF neutralizing
antibody inhibits angiogenesis and tumour growth in vitro and in
an in vivo tumour model (Borgstrom et al, 1996; Presta et al,
1997). If VEGF is responsible for tumour angiogenesis in soft
tissue sarcomas, therapeutic strategies using either specific anti-
bodies or antisense RNA to VEGF, may inhibit tumour angio-
genesis. 
In conclusion, the correlation of tissue VEGF concentration and
disease outcome suggests that angiogenesis may be a potential
prognostic marker in soft tissue sarcomas. In addition, VEGF may
provide a potential target for therapy in soft tissue sarcomas. 
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